Skip to main content

Advertisement

Table 1 Baseline Patient Characteristics

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Characteristics HLA-A*2402 p value
Matched (n = 50) Unmatched (n = 46)
Sex     
  Male 25 24 NS
  Female 25 22  
Age     
  Mean 64.3 63.4 NS
  Standard error 10.9 8  
  Range 36-82 38-77  
Unresectable site    
  Liver 27 35  
  Lung 18 12  
  Dissemination 5 4 NS
  Bone 1 2  
  Lymphnode 13 13  
  Other 5 1  
Number of unresectable sites    
  1 36 30  
  2 9 11  
  3 5 5  
Resection of primary lesion    
  yes 41 43  
  no 9 3 NS
Chemotherapy    
  FOLFOX 48 45  
  XELOX 2 1 NS
  (Bevacizumab) 0 (5)  
Primary minor site    
  Colon 29 36 0.057
  Rectal 21 10  
  1. FOLFOX. infusional fluorouracil. leucovorin. and oxaliplatin: XELOX. capecitabine and oxaliplatin; HLA, human leukocyte antigen; NS. not significant.